nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Bladder pain—Bleomycin—lymphatic system cancer	0.00977	0.00977	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Methotrexate—lymphatic system cancer	0.00947	0.00947	CcSEcCtD
Darifenacin—Stomatitis—Teniposide—lymphatic system cancer	0.00915	0.00915	CcSEcCtD
Darifenacin—Sweating—Teniposide—lymphatic system cancer	0.009	0.009	CcSEcCtD
Darifenacin—Bronchitis—Fludarabine—lymphatic system cancer	0.0089	0.0089	CcSEcCtD
Darifenacin—Injury—Bleomycin—lymphatic system cancer	0.00854	0.00854	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00841	0.00841	CcSEcCtD
Darifenacin—Abnormal vision—Carmustine—lymphatic system cancer	0.00823	0.00823	CcSEcCtD
Darifenacin—Mental disability—Carmustine—lymphatic system cancer	0.00819	0.00819	CcSEcCtD
Darifenacin—Mouth ulceration—Vincristine—lymphatic system cancer	0.00814	0.00814	CcSEcCtD
Darifenacin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00812	0.00812	CcSEcCtD
Darifenacin—Infection—Mechlorethamine—lymphatic system cancer	0.00807	0.00807	CcSEcCtD
Darifenacin—Stomatitis—Fludarabine—lymphatic system cancer	0.00804	0.00804	CcSEcCtD
Darifenacin—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00802	0.00802	CcSEcCtD
Darifenacin—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00801	0.00801	CcSEcCtD
Darifenacin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00789	0.00789	CcSEcCtD
Darifenacin—Sinusitis—Fludarabine—lymphatic system cancer	0.00774	0.00774	CcSEcCtD
Darifenacin—Injury—Carmustine—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Darifenacin—Pharyngitis—Fludarabine—lymphatic system cancer	0.00735	0.00735	CcSEcCtD
Darifenacin—Visual impairment—Fludarabine—lymphatic system cancer	0.00714	0.00714	CcSEcCtD
Darifenacin—Erythema multiforme—Fludarabine—lymphatic system cancer	0.007	0.007	CcSEcCtD
Darifenacin—Face oedema—Carmustine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Darifenacin—Hypertension—Teniposide—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Darifenacin—Urinary retention—Vincristine—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Darifenacin—Confusional state—Teniposide—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Darifenacin—Oedema—Teniposide—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Darifenacin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00598	0.00598	CcSEcCtD
Darifenacin—Infection—Teniposide—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Darifenacin—Stomatitis—Bleomycin—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Darifenacin—Tachycardia—Teniposide—lymphatic system cancer	0.00584	0.00584	CcSEcCtD
Darifenacin—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Darifenacin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00573	0.00573	CcSEcCtD
Darifenacin—Cough—Fludarabine—lymphatic system cancer	0.00562	0.00562	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00562	0.00562	CcSEcCtD
Darifenacin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Darifenacin—Arthralgia—Fludarabine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Darifenacin—Dyspnoea—Teniposide—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Darifenacin—Confusional state—Fludarabine—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Darifenacin—Oedema—Fludarabine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Darifenacin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Darifenacin—Infection—Fludarabine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Darifenacin—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Darifenacin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Darifenacin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Darifenacin—Stomatitis—Carmustine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Darifenacin—Urinary tract infection—Carmustine—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Darifenacin—Rash—Mechlorethamine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Darifenacin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Darifenacin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Darifenacin—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Darifenacin—Weight increased—Mitoxantrone—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Darifenacin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Darifenacin—Stomatitis—Vincristine—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Darifenacin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Darifenacin—Sweating—Vincristine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Darifenacin—Nausea—Mechlorethamine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Darifenacin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Darifenacin—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Darifenacin—Abdominal pain—Teniposide—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Darifenacin—Hallucination—Carmustine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Darifenacin—Sweating—Mitoxantrone—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Darifenacin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Darifenacin—Oedema peripheral—Carmustine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Darifenacin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Darifenacin—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Darifenacin—Visual impairment—Carmustine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Darifenacin—Hallucination—Vincristine—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Darifenacin—Constipation—Fludarabine—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Darifenacin—Pain—Fludarabine—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Darifenacin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Darifenacin—Urethral disorder—Vincristine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Darifenacin—Eye disorder—Carmustine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Darifenacin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Darifenacin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Darifenacin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Darifenacin—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Darifenacin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Darifenacin—Asthenia—Teniposide—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Darifenacin—Pruritus—Teniposide—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Darifenacin—Mental disorder—Carmustine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Darifenacin—Vaginal infection—Methotrexate—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Darifenacin—Cough—Bleomycin—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Darifenacin—Angiopathy—Vincristine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Darifenacin—Diarrhoea—Teniposide—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Darifenacin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Darifenacin—Back pain—Carmustine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Darifenacin—Mental disorder—Vincristine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Darifenacin—Bladder pain—Methotrexate—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Darifenacin—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Darifenacin—Confusional state—Bleomycin—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Darifenacin—Vision blurred—Carmustine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Darifenacin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Darifenacin—Oedema—Bleomycin—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Darifenacin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Darifenacin—Infection—Bleomycin—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Darifenacin—Back pain—Vincristine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Darifenacin—Vomiting—Teniposide—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Darifenacin—Asthenia—Fludarabine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Darifenacin—Rash—Teniposide—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Darifenacin—Dermatitis—Teniposide—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Darifenacin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Darifenacin—Headache—Teniposide—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Darifenacin—Pruritus—Fludarabine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Darifenacin—Back pain—Mitoxantrone—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Darifenacin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Darifenacin—Diarrhoea—Fludarabine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Darifenacin—Hypertension—Carmustine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Darifenacin—Nausea—Teniposide—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Darifenacin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Darifenacin—Hypertension—Vincristine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Darifenacin—Confusional state—Carmustine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Darifenacin—Oedema—Carmustine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Darifenacin—Visual disturbance—Methotrexate—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Darifenacin—Cough—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Darifenacin—Infection—Carmustine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Darifenacin—Vomiting—Fludarabine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Darifenacin—Rash—Fludarabine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Darifenacin—Dermatitis—Fludarabine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Darifenacin—Hypertension—Mitoxantrone—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Darifenacin—Pain—Bleomycin—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Darifenacin—Headache—Fludarabine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Darifenacin—Tachycardia—Carmustine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Darifenacin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Darifenacin—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Darifenacin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Darifenacin—Oedema—Vincristine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Darifenacin—Infection—Vincristine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Darifenacin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Darifenacin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Darifenacin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Darifenacin—Oedema—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Darifenacin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Darifenacin—Nausea—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Darifenacin—Infection—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Darifenacin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Darifenacin—Shock—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Darifenacin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Darifenacin—Insomnia—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Darifenacin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Darifenacin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Darifenacin—Dyspnoea—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Darifenacin—Somnolence—Carmustine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Darifenacin—Insomnia—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Darifenacin—Constipation—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Darifenacin—Pain—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Darifenacin—Breast disorder—Methotrexate—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Darifenacin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Darifenacin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Darifenacin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Darifenacin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Darifenacin—Asthenia—Bleomycin—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Darifenacin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Darifenacin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Darifenacin—Pain—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Darifenacin—Constipation—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Darifenacin—Pruritus—Bleomycin—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Darifenacin—Constipation—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Darifenacin—Pain—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Darifenacin—Abdominal pain—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Darifenacin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Darifenacin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Darifenacin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Darifenacin—Abdominal pain—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Darifenacin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Darifenacin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Darifenacin—Vomiting—Bleomycin—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Darifenacin—Infestation—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Darifenacin—Rash—Bleomycin—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Darifenacin—Dermatitis—Bleomycin—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Darifenacin—Asthenia—Carmustine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Darifenacin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Darifenacin—Sweating—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Darifenacin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Darifenacin—Asthenia—Vincristine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Darifenacin—Diarrhoea—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Darifenacin—Nausea—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Darifenacin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Darifenacin—Dizziness—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Darifenacin—Diarrhoea—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Darifenacin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Darifenacin—Vomiting—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Darifenacin—Dizziness—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Darifenacin—Rash—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Darifenacin—Dermatitis—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Darifenacin—Headache—Carmustine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Darifenacin—Vomiting—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Darifenacin—Rash—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Darifenacin—Dermatitis—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Darifenacin—Headache—Vincristine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Darifenacin—Nausea—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Darifenacin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Darifenacin—Rash—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Darifenacin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Darifenacin—Headache—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Darifenacin—Nausea—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Darifenacin—Nausea—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Darifenacin—Back pain—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Darifenacin—Cough—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Darifenacin—Infection—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Darifenacin—Pain—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Darifenacin—Rash—Methotrexate—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—lymphatic system cancer	0.000982	0.000982	CcSEcCtD
Darifenacin—Headache—Methotrexate—lymphatic system cancer	0.000977	0.000977	CcSEcCtD
Darifenacin—Nausea—Methotrexate—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
